2.4.0.8100070 - Disclosure - Summary of Significant Accounting Policiestruefalsefalse1false falsefalseC_0001269021_20130101_20130630http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and following the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for a fair statement of the Company’s financial information. The results of operations for the six months ended June 30, 2013 are not necessarily indicative of the results to be expected for the year ending December 31, 2013. The condensed balance sheet as of December 31, 2012 has been derived from audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2012 included in the Company’s Prospectus filed pursuant to Rule 424(b)(4) as filed on May 21, 2013 with the SEC. Reverse Stock Split On May 17, 2013, the Company effected a 1-for-10 reverse split of our preferred stock and common stock. Upon the effectiveness of the reverse stock split every 10 shares of outstanding preferred stock and common stock was decreased to one share of preferred stock or common stock, as applicable, the number of shares of common stock into which each outstanding option to purchase common stock is exercisable was proportionately decreased on a 1-for-10 basis, and the exercise price of each outstanding option to purchase common stock was proportionately increased on a 1-for-10 basis. All the shares numbers, share prices and exercise prices have been adjusted within the condensed financial statements, on a retroactive basis, to reflect the 1-for-10 reverse stock split. Additional Capital Requirements We have incurred significant losses and negative cash flows from operations. As of June 30, 2013, we had an accumulated deficit of $242.4 million and cash, cash equivalents and investments of $235.2 million. Our management believes that currently available resources will provide sufficient funds to enable us to meet our obligations for at least the next twelve months based on our current business plans. However, if our anticipated operating results are not achieved in future periods, our management believes that planned expenditures may need to be reduced in order to extend the time period over which the then-available resources would be able to fund our operations. We will need to raise additional capital to fully implement our business plan. Use of Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the condensed financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and other highly liquid investments with original maturities of three months or less from the date of purchase. Investments All investments have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase and reevaluates such designation as of each balance sheet date. Unrealized gains and losses are excluded from earnings and were reported as a component of accumulated comprehensive income. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest and other income (expense), net. Customer Concentration Customers whose collaborative research and development revenue accounted for 10% or more of total revenues were as follows:   <div style="text-align: left;"> <table cellspacing="0" cellpadding="0" style="display: block; text-align: left; border: 0"> <tr> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> <th colspan="7" style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom"> Three Months Ended June 30, </th> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom" colspan="2">   </th> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> <th colspan="9" style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom"> Six Months Ended June 30, </th> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> </tr> <tr> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> <th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> <th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom"> 2013 </th> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom" colspan="2">   </th> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> <th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> <th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom"> 2012 </th> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom" colspan="2">   </th> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> <th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> <th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom"> 2013 </th> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom" colspan="2">   </th> <th style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> <th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> <th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom"> 2012 </th> <th colspan="3" style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </th> </tr> <tr> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom"> Novartis AG              </td> <td style="background-color:#cff0fc; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">—</td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom" colspan="2">   </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">  100</td> <td style="background-color:#cff0fc; padding-top:0.7pt; vertical-align:bottom; text-align:right"></td><td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:left">%</td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">—</td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom" colspan="2">   </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">  100</td> <td style="background-color:#cff0fc; padding-top:0.7pt; vertical-align:bottom; text-align:right"></td><td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:left" colspan="2">%</td> </tr> <tr> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom"> Bristol-Myers Squibb Company and Pfizer Inc.              </td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">  43</td> <td style="padding-top:0.7pt; vertical-align:bottom; text-align:right"></td><td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:left">%</td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">—</td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom" colspan="2">   </td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">  54</td> <td style="padding-top:0.7pt; vertical-align:bottom; text-align:right"></td><td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:left">%</td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">—</td> <td colspan="3" style="padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> </tr> <tr> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom"> Bayer Pharma, AG and Janssen Pharmaceuticals, Inc.              </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">  51</td> <td style="background-color:#cff0fc; padding-top:0.7pt; vertical-align:bottom; text-align:right"></td><td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:left">%</td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">—</td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom" colspan="2">   </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">  43</td> <td style="background-color:#cff0fc; padding-top:0.7pt; vertical-align:bottom; text-align:right"></td><td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:left">%</td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> <td style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom; text-align:right">—</td> <td colspan="3" style="background-color:#cff0fc; padding-right:0.7pt; padding-top:0.7pt; vertical-align:bottom">   </td> </tr> </table> </div> Deferred Offering Costs Deferred offering costs, which primarily consist of direct incremental legal, accounting and printing fees incurred in the preparation of the IPO, were capitalized. The deferred offering costs were offset against IPO proceeds upon completion of the offering in May 2013. As of December 31, 2012, $1.6 million of deferred offering costs were capitalized in other assets on the balance sheets. There were no remaining amounts deferred at June 30, 2013. Revenue Recognition We generate revenue from collaboration and license agreements for the development and commercialization of our products. Collaboration and license agreements may include non-refundable upfront license fees, partial or complete reimbursement of research and development costs, contingent consideration payments based on the achievement of defined collaboration objectives and royalties on sales of commercialized products. Our performance obligations under our collaborations include the transfer of intellectual property rights (licenses), obligations to provide research and development services and related materials and obligations to participate on certain development and/or commercialization committees with the collaborators. Payments that are contingent upon achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved. Milestones are defined as an event that can only be achieved based on our performance and there is substantive uncertainty about whether the event will be achieved at the inception of the arrangement. Events that are contingent only on the passage of time or only on counterparty performance are not considered milestones subject to this guidance. Further, the amounts received must relate solely to prior performance, be reasonable relative to all of the deliverables and payment terms within the agreement and commensurate with our performance to achieve the milestone after commencement of the agreement. Amounts from sales of licenses are recognized as revenue, as licensing of intellectual property is one of our principal or major ongoing activities. Amounts received as funding of research and development activities are recognized as revenue if the collaboration arrangement involves the sale of our research or development services at amounts that exceed our cost. However, such funding is recognized as a reduction in research and development expense when we engage in a research and development project jointly with another entity, with both entities participating in project activities and sharing costs and potential benefits of the arrangement. Amounts related to research and development funding are recognized as the related services or activities are performed, in accordance with the contract terms. Payments may be made to or by us based on the number of full-time equivalent researchers assigned to the collaboration project and the related research and development expenses incurred. Foreign Currency Transactions and Hedging We have transactions denominated in foreign currencies, primarily the Euro, and, as a result, are exposed to changes in foreign currency exchange rates. We manage a portion of these cash flow exposures through the purchase of Euros and the use of foreign currency forward contracts. Our foreign currency forward contracts are not designated as hedges for accounting purposes. Gains or losses on foreign currency forward contracts are intended to offset gains or losses on the underlying net exposures in an effort to reduce the earnings and cash flow volatility resulting from fluctuating foreign currency exchange rates. Foreign currencies and our foreign currency forward contracts are marked to market at the end of each period and recorded as gains and losses in the condensed statements of operations. Our foreign exchange forward contracts expose us to credit risk to the extent that the counterparty, a major financial institution, is unable to meet the terms of the agreement. Our management does not expect material losses as a result of defaults by the counterparty. Net Income (Loss) per Share Attributable to Common Stockholders Basic and diluted net income (loss) per share attributable to common stockholders is calculated in conformity with the two-class method required for companies with participating securities. Under the two-class method, in periods when we have net income, basic net income attributable to common stockholders is determined by allocating undistributed earnings, calculated as net income less current period convertible preferred stock noncumulative dividends, between the common stock and the convertible preferred stock. In computing diluted net income attributable to common stockholders, undistributed earnings are re-allocated to reflect the potential impact of dilutive securities. Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net income per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period. In periods when we have incurred a net loss, convertible preferred stock, options and warrants to purchase common stock and convertible preferred stock warrants are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is antidilutive. </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.No definition available.false0Summary of Significant Accounting PoliciesfalseSummary of Significant Accounting PoliciesUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.portola.com/20130630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies11